Pro-Dex Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.38 Intrinsic Value $44.20median of 6 methods · middle span $31-$72based on filings through 31 Mar 2026 Market Price $65.36Price as of 1 Oct 2026 OvervaluedIntrinsic value is 32% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $209.4M Enterprise Value $218.7M Shares Outstanding 3.3M diluted Moat Rating Wide Next Earnings Date29 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Pro-Dex Inc. (PDEX) is demonstrating robust operational momentum, highlighted by a record-breaking fiscal Q3 2026. The company's core medical device business is anchored by a critical three-year contract extension (through calendar 2028) with its largest customer, securing long-term demand for its next-generation orthopedic handpieces. To support this volume expansion and secure its supply chain, Pro-Dex strategically acquired its key supplier, Advanced Precision Machining (APM), in February 2026. This acquisition not only internalizes high-precision machining but also introduces high-margin aerospace and defense revenue streams. Furthermore, the monetization of its Monogram Technologies investment provides substantial non-dilutive cash inflows, significantly strengthening its balance sheet. Despite near-term margin pressure from unfavorable product mix and elevated integration costs, Pro-Dex's deep OEM relationships, proprietary torque-limiting software, and expanded capacity position it for sustained profitable growth. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$70.00 Mean target$70.00 High · most bullish analyst$70.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects integration bottlenecks with APM, leading to prolonged elevated operating expenses and supply chain disruptions. Customer concentration remains a major vulnerability; any reduction in order volumes from the largest customer or delays in next-generation product rollouts would severely impact the top line. Margins remain compressed near 29-30% due to persistent unfavorable product mix and tariff pressures, limiting the stock's upside. Base CaseCentral scenario The base case assumes steady execution of the extended orthopedic handpiece contract, successful integration of APM to drive manufacturing efficiencies, and the successful commercial launch of the Helios CMF driver. Revenue is projected to grow at a 12-15% CAGR, with gross margins stabilizing around 32-33% as product mix improves and APM synergies are realized. The company is expected to occasionally benefit from Monogram milestone payments, supporting a target price of $70.00. Bull CaseUpside scenario Pro-Dex is significantly mispriced as the market values it as a stagnant, Stryker-dependent contract manufacturer, failing to price in the contractual exclusivity and high-margin recurring revenue from the Zimmer Biomet-Monogram mBôS partnership. The commercial launch of the mBôS platform in early 2027 represents a massive operating leverage pivot, transitioning Pro-Dex from lower-margin engineering-for-hire to high-margin exclusive disposable manufacturing (burrs and sagittal saws) with a 24-month FDA re-validation barrier protecting its monopoly status. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |